Ask AI

Overcoming Endocrine Resistance in HR+/HER2- MBC: Tailoring Treatment for Patients With ESR1- and PI3K/AKT/PTEN-Altered Disease Post-ET Progression

Gain in-depth knowledge on how to integrate novel and emerging agents to manage patients with HR-positive/HER2-negative MBC harboring ESR1 or PIK3CA/AKT1/PTEN alterations following disease progression on endocrine therapy. View an on-demand webcast of a live webinar, download the associated slideset for use in your clinic, and review the expert-authored answers to frequently asked questions.

Share

Program Content

No activities added yet

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from AstraZeneca, Lilly and Stemline Therapeutics, Inc.

AstraZeneca

Lilly

Stemline Therapeutics, Inc.